表紙
市場調查報告書

腦炎:開發中產品分析

Encephalitis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 465220
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
腦炎:開發中產品分析 Encephalitis - Pipeline Review, H2 2019
出版日期: 2019年08月30日內容資訊: 英文 47 Pages
簡介

腦炎是腦組織的發炎。有兩種主要類型:原發性和繼發性。當病毒直接感染腦和脊髓時就是原發性腦炎。繼發性腦炎則是身體其他部位感染,然後傳染到大腦。原因包括常見病毒,兒童期病毒和蟲媒病毒。風險因素包括年齡和免疫系統衰弱。症狀包括發熱,頭痛,嘔吐,頸部僵硬,昏迷和幻覺。治療包括止痛藥,皮質類固醇,抗驚厥藥和鎮靜劑。

本報告提供腦炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

腦炎;概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aeterna Zentaris Inc
  • CEL-SCI Corp
  • Prosetta Biosciences Inc
  • Sage Therapeutics Inc

藥物簡介

  • Amphotericin B sodium
  • CEL-1000
  • miltefosine
  • PAV-645
  • pneumococcal (23-valent) vaccine
  • Polyglactin 370 for Acute Encephalitis Syndrome
  • SAGE-718
  • Small Molecules for Viral Infections
  • VY-OZ

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11368IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis - Pipeline Review, H2 2019, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.

Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune systems. Symptoms include fever, headache, vomiting, stiff neck, coma and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants and sedatives.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 7 respectively.

Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalitis (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Encephalitis - Overview
  • Encephalitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Encephalitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Encephalitis - Companies Involved in Therapeutics Development
    • CEL-SCI Corp
    • F. Hoffmann-La Roche Ltd
    • Knight Therapeutics Inc
    • Sage Therapeutics Inc
  • Encephalitis - Drug Profiles
    • Amphotericin B sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cerium dioxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • miltefosine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ocrelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumococcal (13-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumococcal (23-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyglactin 370 for Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Encephalitis - Dormant Projects
  • Encephalitis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 06, 2018: Knight receives adverse notice of reassessment from CRA
      • Jun 28, 2017: FDA Grants Profounda Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis (GAE) with Miltefosine
      • Dec 17, 2016: Profounda receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine
      • Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)
      • Dec 15, 2015: U.S. Issues Patent on Corifungin
      • Feb 26, 2013: National Institutes of Health Supports Acea's Research
      • Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. Naegleria
      • Aug 22, 2011: FDA Grants 2nd Orphan drug designation
      • Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Encephalitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Encephalitis - Pipeline by CEL-SCI Corp, H2 2019
  • Encephalitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Encephalitis - Pipeline by Knight Therapeutics Inc, H2 2019
  • Encephalitis - Pipeline by Sage Therapeutics Inc, H2 2019
  • Encephalitis - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Encephalitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top